Bcal Diagnostics Limited (ASX:BDX)

13.0¢

right-arrow Created with Sketch. -0.005 (-3.7%)
MCAP $27.92M
Last trade 10.41am 30/11/2021 20mins delayed

Latest Announcements

23/11/2021BDXBcal Diagnostics Limited
22/11/2021BDXBcal Diagnostics Limited
22/11/2021BDXBcal Diagnostics Limited
133
MCap
08/11/2021BDXBcal Diagnostics Limited
03/11/2021 Price SensitivePSBDXBcal Diagnostics Limited
28/10/2021 Price SensitivePSBDXBcal Diagnostics Limited
26/10/2021BDXBcal Diagnostics Limited
21/10/2021BDXBcal Diagnostics Limited

Company Overview

BCAL Diagnostics Limited (BCAL) is an Australia-based screening and diagnostic company. The Company is developing a blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, accurate and available to all women regardless of age, race and geographic location. It has developed a non-invasive blood test for the detection of breast cancer. The Company is developing an in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vehicles (EVs) from a patient's plasma or blood sample to diagnose the presence of cancer cells in a patient’s body. BCAL has partnered with integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across jurisdictions.

Search Previous Announcements